Evidence map›Paper›PMID 41572423›Full record

ArticleThe oncologist2026

Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysis.

Ogechukwu A Asogwa, Linda Dirven, Neil K Aaronson, Brigitta G Baumert, Martin van den Bent, Alba A Brandes, Paul M Clement, Corneel Coens, Olivier Chinot, Thierry Gorlia and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Ogechukwu A AsogwaDepartment of Neurology, Leiden University Medical Center, ZA 2333, Leiden, The Netherlands.ORCID 0000-0001-6300-332X
Linda DirvenDepartment of Neurology, Leiden University Medical Center, ZA 2333, Leiden, The Netherlands.
Neil K AaronsonDivision of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Postbus 90203 1006 BE Amsterdam, The Netherlands.ORCID 0000-0003-2574-4850
Brigitta G BaumertInstitute of Radiation-Oncology, Cantonal Hospital Graubünden, 7000 Chur, Switzerland.
Martin van den BentThe Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam 3015GD, The Netherlands.
Alba A BrandesDepartment of Medical Oncology, AUSL-IRCCS Scienze Neurologiche, Bologna 40124, Italy.
Paul M ClementDepartment of Oncology, KU Leuven, Leuven 3000, Belgium.
Corneel CoensEuropean Organisation for Research and Treatment of Cancer, Brussels 1200, Belgium.
Olivier ChinotDepartment of Neuro-Oncology, Aix-Marseille Université, CHU Timone, AP-HM, Marseille, France.
Thierry GorliaEuropean Organisation for Research and Treatment of Cancer, Brussels 1200, Belgium.
Ulrich HerrlingerDepartment of Neurooncology, Center for Neurology and Center for Integrated Oncology, University of Bonn Medical Center, Bonn, Germany.
Caroline HertlerDepartment of Neurology, University Hospital and University of Zurich, Zurich 8091, Switzerland.ORCID 0000-0001-6181-2895
Florence Keime-GuibertInstitut de Recherche International Servier 22, Gif sur Yvette 91190, France.
Emilie Le RhunDepartment of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich 8091,  Switzerland.
Luigi LimEuropean Organisation for Research and Treatment of Cancer, Brussels 1200, Belgium.
Annika MalmströmClinical Department of Geriatrics and Palliative Medicine in Linköping, 581 85, Linköping, Sweden.
Christine MarosiDepartment of Medicine I, Division of Oncology, Medical University of Vienna, Vienna 1090, Austria.ORCID 0000-0003-0631-672X
Francesca MartinelliEuropean Organisation for Research and Treatment of Cancer, Brussels 1200, Belgium.
Matthijs van der MeulenDepartment of Neurology, Leiden University Medical Center, ZA 2333, Leiden, The Netherlands.
Kathy OliverInternational Brain Tumour Alliance, Tadworth KT20 5WQ, United Kingdom.ORCID 0000-0002-8317-2881
Andrea PaceIRCCS Regina Elena Cancer Institute, Neuro-Oncology Unit, Rome 00144, Italy.ORCID 0000-0002-9407-6916
Claudia PanciroliClinical Investigation Unit-Institut Català d'Oncologia, Badalona 08916, Spain. Neurology Unit-I.R.C.C.S. Ospedale San Raffaele, Milan 20132,  Italy.
Jaap C ReijneveldDepartment of Neurology and Brain Tumour Center Amsterdam, Amsterdam University Medical Center, Amsterdam 1105, The Netherlands.
Mirjam RenovanzDepartment of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Eberhard Karls University, Tübingen 72074, Germany.ORCID 0000-0002-2824-3720
Patrick RothDepartment of Neurology, University Hospital and University of Zurich, Zurich 8091, Switzerland.ORCID 0000-0003-3897-214X
Clemens SeidelDepartment of Radiation Oncology, University of Leipzig Medical Center, Leipzig 04103, Germany.
Roger StuppDepartments of Oncology and Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne CH-1015, Switzerland.ORCID 0000-0002-5483-3118
Wolfgang WickNeurology Clinic and European Centre for Neurooncology (EZN), University Hospital Heideberg, Heidelberg 69120, Germany.ORCID 0000-0002-6171-634X
Michael WellerDepartment of Neurology, University Hospital and University of Zurich, Zurich 8091, Switzerland.ORCID 0000-0002-1748-174X
Martin J B TaphoornDepartment of Neurology, Leiden University Medical Center, ZA 2333, Leiden, The Netherlands.
Johan A F KoekkoekDepartment of Neurology, Leiden University Medical Center, ZA 2333, Leiden, The Netherlands.ORCID 0000-0002-3648-9616
EORTC Quality of Life Group and the EORTC Brain Tumor Group

Funding

European Organisation for Research and TreatmentQuality of Life Group 013-2021
6 · The paper itself

Abstract

backgroundWe assessed the clinical relevance of age and sex as risk factors for health-related quality of life (HRQoL) in patients with adult-type diffuse glioma. MATERIALS AND

methodsThe CODAGLIO 2.0 database contains 16 randomized trials from 5369 patients with glioma. Patients' HRQoL was assessed using EORTC QLQ-C30 and QLQ-BN20 questionnaires. In 8 HRQoL scales, we compared mean HRQoL at baseline with the general population and evaluated factors associated with HRQoL over time using linear mixed models (LMMs). We used the anchor-based minimally important difference to interpret clinically relevant changes.

resultsWe included 4301 patients with baseline HRQoL followed up to 3 months. Compared to the general population, patients with glioma at baseline had statistically and clinically relevant worse HRQoL, which was still evident after stratifying by age and sex groups. In LMMs, compared to patients aged ≤60 years, those >60 years had statistically significant associations with worse physical functioning: -2.40 (95% confidence interval [CI] -4.14 to -0.71), better social: 4.88 (2.68-7.30) and role: 3.79 (1.39-6.16) functioning, and less fatigue: -3.43 (-5.44 to -1.33) and pain: -4.56 (-6.18 to -2.93). Compared to men, women had statistically significant associations with worse physical and social functioning and more fatigue and pain. Associations between age, sex, and HRQoL were not clinically relevant. Performance status had clinically relevant associations in 5/8 scales.

conclusionPatients with glioma have clinically relevant worse HRQoL compared to the general population. There are statistically but not clinically significant associations between age, sex, and certain HRQoL scales.

Indexed as

Brain NeoplasmsGliomaQuality of LifeAdultAgedAge FactorsFemaleHumansMaleMiddle AgedRisk FactorsSex FactorsSurveys and Questionnairesagebrain tumorgeneral population normative datahealth-related quality of life (HRQoL)sex

Identifiers

PMID41572423
PMCPMC12948937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.